JP2016536321A - カナグリフロジンのｂ形結晶、ｃ形およびｄ形 - Google Patents

カナグリフロジンのｂ形結晶、ｃ形およびｄ形 Download PDF

Info

Publication number
JP2016536321A
JP2016536321A JP2016530967A JP2016530967A JP2016536321A JP 2016536321 A JP2016536321 A JP 2016536321A JP 2016530967 A JP2016530967 A JP 2016530967A JP 2016530967 A JP2016530967 A JP 2016530967A JP 2016536321 A JP2016536321 A JP 2016536321A
Authority
JP
Japan
Prior art keywords
ray diffraction
diffraction pattern
measured
canagliflozin
values
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016530967A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016536321A5 (https=
Inventor
チェン、ミンホア
チャン、イェンフォン
チャオ、イー
チャオ、イェー
チャン、シアオユイ
ヤン、チャオホイ
ルー、フェイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crystal Pharmatech Co Ltd
Original Assignee
Crystal Pharmatech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201310556655.2A external-priority patent/CN103554092A/zh
Priority claimed from CN201310617597.XA external-priority patent/CN103588762A/zh
Application filed by Crystal Pharmatech Co Ltd filed Critical Crystal Pharmatech Co Ltd
Publication of JP2016536321A publication Critical patent/JP2016536321A/ja
Publication of JP2016536321A5 publication Critical patent/JP2016536321A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2016530967A 2013-11-11 2014-11-11 カナグリフロジンのｂ形結晶、ｃ形およびｄ形 Pending JP2016536321A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN201310556655.2A CN103554092A (zh) 2013-11-11 2013-11-11 1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯的新晶型B及其制备方法
CN201310556655.2 2013-11-11
CN201310617597.X 2013-11-27
CN201310617597.XA CN103588762A (zh) 2013-11-27 2013-11-27 坎格列净的新晶型及其制备方法
CN201410542984.6A CN104356121A (zh) 2013-11-11 2014-10-14 1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯的晶型B及其制备方法
CN201410542984.6 2014-10-14
CN201410593413.5A CN104356122B (zh) 2013-11-27 2014-10-29 坎格列净的晶型及其制备方法
CN201410593413.5 2014-10-29
PCT/IB2014/003013 WO2015071761A2 (en) 2013-11-11 2014-11-11 Crystalline forms b, c, and d of canagliflozin

Publications (2)

Publication Number Publication Date
JP2016536321A true JP2016536321A (ja) 2016-11-24
JP2016536321A5 JP2016536321A5 (https=) 2017-12-07

Family

ID=53141472

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016530967A Pending JP2016536321A (ja) 2013-11-11 2014-11-11 カナグリフロジンのｂ形結晶、ｃ形およびｄ形

Country Status (4)

Country Link
US (1) US20160280731A1 (https=)
EP (1) EP3068779A4 (https=)
JP (1) JP2016536321A (https=)
WO (1) WO2015071761A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015139386A1 (zh) 2014-03-19 2015-09-24 杭州普晒医药科技有限公司 坎格列净一水合物及其晶型、它们的制备方法和用途
WO2016016774A1 (en) * 2014-07-31 2016-02-04 Sun Pharmaceutical Industries Limited Crystalline forms of canagliflozin
CN104530024B (zh) * 2015-02-04 2017-08-08 上海迪赛诺药业有限公司 1‑(β‑D‑吡喃葡糖基)‑4‑甲基‑3‑[5‑(4‑氟苯基)‑2‑噻吩基甲基]苯的晶型及其制备方法
ES2896101T3 (es) 2015-09-15 2022-02-23 Laurus Labs Ltd Cocristales de inhibidores de SGLT2, procedimiento para su preparación y composiciones farmacéuticas de los mismos
CZ2015824A3 (cs) 2015-11-20 2017-05-31 Zentiva, K.S. Krystalická forma Canagliflozinu a způsob její přípravy

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519698A (ja) * 2000-01-07 2003-06-24 トランスフォーム ファーマスーティカルズ，インコーポレイテッド 多様な固体形態のハイスループットでの形成、同定および分析
JP2010511602A (ja) * 2006-12-04 2010-04-15 田辺三菱製薬株式会社 １−（β−Ｄ−グルコピラノシル）−４−メチル−３−［５−（４−フルオロフェニル）−２−チエニルメチル］ベンゼン１／２水和物の結晶形
JP2010539092A (ja) * 2007-09-10 2010-12-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｓｇｌｔの阻害物質として有用な化合物の製造方法
JP2013508284A (ja) * 2009-10-14 2013-03-07 ヤンセン ファーマシューティカ エヌ．ベー． Ｓｇｌｔ２の阻害物質として有用な化合物の調製プロセス
JP2013526482A (ja) * 2010-05-11 2013-06-24 田辺三菱製薬株式会社 カナグリフロジン含有錠剤
CN103980262A (zh) * 2014-04-01 2014-08-13 天津大学 卡格列净的b晶型及其结晶制备方法
CN104119324A (zh) * 2014-07-23 2014-10-29 齐鲁天和惠世制药有限公司 一种卡格列净的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2911261A1 (en) * 2013-05-08 2014-11-13 Lek Pharmaceuticals D.D. Novel crystalline hydrates of 1-(.beta.-d-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene
CN103588762A (zh) * 2013-11-27 2014-02-19 苏州晶云药物科技有限公司 坎格列净的新晶型及其制备方法
CN103554092A (zh) * 2013-11-11 2014-02-05 苏州晶云药物科技有限公司 1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯的新晶型B及其制备方法
WO2016016774A1 (en) * 2014-07-31 2016-02-04 Sun Pharmaceutical Industries Limited Crystalline forms of canagliflozin

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519698A (ja) * 2000-01-07 2003-06-24 トランスフォーム ファーマスーティカルズ，インコーポレイテッド 多様な固体形態のハイスループットでの形成、同定および分析
JP2010511602A (ja) * 2006-12-04 2010-04-15 田辺三菱製薬株式会社 １−（β−Ｄ−グルコピラノシル）−４−メチル−３−［５−（４−フルオロフェニル）−２−チエニルメチル］ベンゼン１／２水和物の結晶形
JP2010539092A (ja) * 2007-09-10 2010-12-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｓｇｌｔの阻害物質として有用な化合物の製造方法
JP2013508284A (ja) * 2009-10-14 2013-03-07 ヤンセン ファーマシューティカ エヌ．ベー． Ｓｇｌｔ２の阻害物質として有用な化合物の調製プロセス
JP2013526482A (ja) * 2010-05-11 2013-06-24 田辺三菱製薬株式会社 カナグリフロジン含有錠剤
CN103980262A (zh) * 2014-04-01 2014-08-13 天津大学 卡格列净的b晶型及其结晶制备方法
CN104119324A (zh) * 2014-07-23 2014-10-29 齐鲁天和惠世制药有限公司 一种卡格列净的制备方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"新医薬品の規格及び試験方法の設定について", 医薬審発第５６８号, JPN6010021254, 2001, ISSN: 0003838778 *
BYRN S: "PHARMACEUTICAL SOLIDS: A STRATEGIC APPROACH TO REGULATORY CONSIDERATIONS", PHARMACEUTICAL RESEARCH, vol. V12 N7, JPN5013009960, 1 July 1995 (1995-07-01), US, pages 945 - 954, ISSN: 0003838782 *
大島寛: "結晶多形・擬多形の析出挙動と制御", PHARM STAGE, vol. 6, no. 10, JPN6011001457, 15 January 2007 (2007-01-15), pages 48 - 53, ISSN: 0003838779 *
山野光久: "医薬品のプロセス研究における結晶多形現象への取り組み", 有機合成化学協会誌, vol. 65, no. 9, JPN6010003277, 1 September 2007 (2007-09-01), pages 907 - 69, ISSN: 0003838781 *
川口洋子ら: "医薬品と結晶多形", 生活工学研究, vol. 4, no. 2, JPN6014015069, 2002, pages 310 - 317, ISSN: 0003838777 *
高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0003838780 *

Also Published As

Publication number Publication date
US20160280731A1 (en) 2016-09-29
EP3068779A4 (en) 2017-06-28
EP3068779A2 (en) 2016-09-21
WO2015071761A3 (en) 2015-09-24
WO2015071761A2 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
JP6470761B2 (ja) レシヌラドおよびそのナトリウム塩の結晶形態
AU2017373784B2 (en) Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists
AU2015330554B2 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
JP2016536321A (ja) カナグリフロジンのｂ形結晶、ｃ形およびｄ形
KR101490329B1 (ko) 피마살탄 포타슘염의 일수화물 결정, 그 제조방법, 및 그를 포함하는 약제학적 조성물
JP2023509242A (ja) 新規なエンパグリフロジンの共結晶
JP2019518008A (ja) ナトリウム−グルコース結合輸送体阻害剤のアミン溶媒和物、その調製方法およびその適用
US20140073791A1 (en) Novel salts of sitagliptin, process for the preparation and pharmaceutical composition thereof
WO2011085130A1 (en) Solid state forms of fosamprenavir calcium salt and process for preparation thereof
EP3704124A1 (en) Crystalline salt of a tricyclic poly(adp-ribose) polymerase inhibitor
HK40079890A (en) Compositions and methods related to picolinylpiperidine 5-ht1f agonists
HK40079891A (en) Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists
WO2022199707A1 (zh) 哌马色林药用盐、制备方法、含其的药物组合物及应用
HK40116055A (zh) 结构化α-2A肾上腺素受体激动剂的异苯并二氢吡喃-咪唑的新硫酸盐形式
WO2020151672A1 (zh) 一种达格列净晶型及其制备方法和用途
HK40007699A (en) Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists
HK40007699B (en) Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists
EA046754B1 (ru) Композиция, связанная с пиридиноилпиперидиновыми агонистами 5-ht1f
EA041348B1 (ru) Композиции и способы, связанные с пиридиноилпиперидиновыми агонистами 5-ht1f

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160713

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20160713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171026

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180717

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190312